ArticleMolecular therapy : the journal of the American Society of Gene Therapy2012
Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- mBiomolecules · 2026Review
- Review
- Efficiency and safety of five different agents forFrontiers in molecular biosciences · 2026Article
- Autologous platelet delivery of siRNAs by autologous plasma protein self-assembled nanoparticles for the treatment of acute kidney injury.Journal of nanobiotechnology · 2025Article
- An Evaluation of Skin and Immunological Responses after Using a Novel Cross-Linked Porcine-Based Dermal Injectable Collagen with Lidocaine for Nasolabial Fold Correction.Journal of clinical medicine · 2024Article
- The emerging potential of siRNA nanotherapeutics in treatment of arthritis.Asian journal of pharmaceutical sciences · 2023Review
- Modified chitosan for effective renal delivery of siRNA to treat acute kidney injury.Biomaterials · 2022Article
- Preferential siRNA delivery to injured kidneys for combination treatment of acute kidney injury.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Atelocollagen Application in Human Periodontal Tissue Treatment-A Pilot Study.Life (Basel, Switzerland) · 2020Article
- Sodium chloride promotes tissue inflammation via osmotic stimuli in subtotal-nephrectomized mice.Laboratory investigation; a journal of technical methods and pathology · 2017Article
- Delivery strategies and potential targets for siRNA in major cancer types.Advanced drug delivery reviews · 2016Review
- Tumor-suppressive effects of atelocollagen-conjugated hsa-miR-520d-5p on un-differentiated cancer cells in a mouse xenograft model.BMC cancer · 2016Article
- Sustained delivery of siRNA/PEI complex from in situ forming hydrogels potently inhibits the proliferation of gastric cancer.Journal of experimental & clinical cancer research : CR · 2016Article
- RNA interference targeting carbohydrate sulfotransferase 3 diminishes macrophage accumulation, inhibits MMP-9 expression and promotes lung recovery in murine pulmonary emphysema.Respiratory research · 2015Article
- Clinical experiences with systemically administered siRNA-based therapeutics in cancer.Nature reviews. Drug discovery · 2015Review
- AMIGO2, a novel membrane anchor of PDK1, controls cell survival and angiogenesis via Akt activation.The Journal of cell biology · 2015Article
- Therapeutic potential of siRNA and DNAzymes in cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Review
- Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- A collagen-based scaffold delivering exogenous microrna-29B to modulate extracellular matrix remodeling.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- High-density lipoproteins for the systemic delivery of short interfering RNA.Expert opinion on drug delivery · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Short interfering RNA (siRNA) is a potent activator of the mammalian innate immune system. When considering possible clinical applications of siRNA for humans, the adverse immunostimulatory effects must also be taken into account. Here, we show that atelocollagen-mediated systemic delivery of siRNA without chemical modifications did not cause any immunostimulation in both animals and human peripheral blood mononuclear cells (PBMCs), even if the siRNA harbored an interferon (IFN)-inducible sequence. In contrast, systemic delivery of immunostimulatory RNA (isRNA)-mediated by a cationic lipid (such as Invivofectamine) induced potent type-I IFNs and inflammatory cytokines. Regarding the mechanism by which the isRNA/atelocollagen complex avoided adverse effects on immunostimulation, we revealed that this complex was not incorporated into PBMCs. On the other hand, Invivofectamine delivered isRNA into PBMCs. The use of either atelocollagen or Invivofectamine as a vehicle elicited significant and undistinguishable therapeutic effects in a contact hypersensitivity (CHS) inflammatory model mouse, when we intravenously injected the siRNA targeting monocyte chemoattractant protein-1 as the complex. For the goal of realizing siRNA-based medicines for humans, atelocollagen is an excellent and promising delivery vehicle, and it has the useful advantage of evading detection by the "radar" of innate immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.